The square-planar and trigonal–bipyramidal coordination environment around the Pt and As atom, respectively, each are distorted, with a τ5 value of 0.794 and 0.711 for arsenic in (1) and (2), respectively.
Keywords: crystal structure, arsenoplatin, platinum, cisplatin
Abstract
Each central platinum(II) atom in the crystal structures of chlorido[dihydroxybis(1-iminoethoxy)arsanido-κ3 N,As,N′]platinum(II), [Pt(C4H10AsN2O4)Cl] (1), and of chlorido[dihydroxybis(1-iminopropoxy)arsanido-κ3 N,As,N′]platinum(II), [Pt(C6H14AsN2O4)Cl] (2), is coordinated by two nitrogen donor atoms, a chlorido ligand and to arsenic, which, in turn, is coordinated by two oxygen donor ligands, two hydroxyl ligands and the platinum(II) atom. The square-planar and trigonal–bipyramidal coordination environments around platinum and arsenic, respectively, are significantly distorted with the largest outliers being 173.90 (13) and 106.98 (14)° for platinum and arsenic in (1), and 173.20 (14)° and 94.20 (9)° for (2), respectively. One intramolecular and four classical intermolecular hydrogen-bonding interactions are observed in the crystal structure of (1), which give rise to an infinite three-dimensional network. A similar situation (one intramolecular and four classical intermolecular hydrogen-bonding interactions) is observed in the crystal structure of (2). Various π-interactions are present in (1) between the platinum(II) atom and the centroid of one of the five-membered rings formed by Pt, As, C, N, O with a distance of 3.7225 (7) Å, and between the centroids of five-membered (Pt, As, C, N, O) rings of neighbouring molecules with distances of 3.7456 (4) and 3.7960 (6) Å. Likewise, weak π-interactions are observed in (2) between the platinum(II) atom and the centroid of one of the five-membered rings formed by Pt, As, C, N, O with a distance of 3.8213 (2) Å, as well as between the Cl atom and the centroid of a symmetry-related five-membered ring with a distance of 3.8252 (12) Å. Differences between (2) and the reported polymorph [Miodragović et al. (2013 ▸). Angew. Chem. Int. Ed. 52, 10749–10752] are discussed.
Chemical context
Platinum and arsenic compounds have shown great versatility in terms of applications in the biological and medicinal fields (Reedijk, 2009 ▸). Platinum compounds are still the most widely used drugs in the fight against cancer in spite of the serious side effects and the resistance of some types of cancers (Miller et al., 2002 ▸; Basu & Krishnamurthy, 2010 ▸; Jakupec et al., 2003 ▸; Kauffman et al., 2010 ▸; Wheate et al., 2010 ▸; Rosenberg et al., 1965 ▸; Marino et al., 2017 ▸; Aabo et al., 1998 ▸; Kelland, 2007 ▸; Shi et al., 2019 ▸). Tumoral malignancies have a high lethality rate and are among the most widespread and difficult diseases to treat. The need for the development of new drugs and treatment alternatives has increased as many of the available effective drugs are comparable and similar to each other (Ott, 2009 ▸; Burchenal, 1978 ▸). Platinum-based antitumour agents have guided and constructed the current tumor chemotherapy treatment, but the side effects complicate and inhibit their clinical application (Rosenberg et al., 1965 ▸; Marino et al., 2017 ▸; Basu & Krishnamurthy, 2010 ▸; Aabo et al., 1998 ▸; Kelland, 2007 ▸; Shi et al., 2019 ▸). Drug resistance is a major limiting factor in terms of the range of tumours that can be treated and the improvement of the therapy (Marino et al., 2017 ▸). Arsenic trioxide was approved by the FDA in 2000 for the treatment of acute promyelocytic leukemia, and since then several studies have shown that the combinatorial employment of arsenic and platinum-based cancer drugs has shown significant therapeutic potential (Wang et al., 2004 ▸; Shen et al., 2004 ▸; Emadi & Gore, 2010 ▸; Zhang et al., 2009 ▸, 2010 ▸). These results led to the synthesis of complexes containing both platinum and arsenic (Swindell et al., 2013 ▸; Miodragović et al., 2013 ▸, 2019 ▸), which were called arsenoplatins. Initial results indicate that these complexes are able to bypass drug-resistance mechanisms that lower the effect of cisplatin and have higher cytotoxicity than cisplatin in some cases. To date, the studies of Miodragović et al. (2013 ▸, 2019 ▸) are the only crystallographic data available in the CCDC (Groom et al., 2016 ▸).
The structures reported here, [Pt(C4H10AsN2O4)Cl] (1), and [Pt(C6H14AsN2O4)Cl], (2), expand on this work and form part of an ongoing study on arsenoplatins, their solid- and solution-state behaviour and evaluation thereof.
Database survey
Two crystal structures similar to (1) were found after a search of the Cambridge Structure Database (CSD, Version 5.40, update of November 2019; Groom et al., 2016 ▸), both of which (ODOHAS, ODOHEW) were reported by Miodragović et al. (2013 ▸, 2019 ▸). They consist of the same arsenoplatin complex as (1), accompanied by an acetamide hemihydrate and acetamide solvent species in the unit cell, and crystallize in the P
and P21/n space groups, respectively. The search also revealed that (2) represents a polymorph, with the first crystal structure determination (ODOGOF; Miodragović et al., 2013 ▸) in the orthorhombic space group type Pbca, in contrast to space group type P21/c of (2).
Structural commentary
In (1) the square-planar coordination environment around platinum(II) is defined by two nitrogen donor atoms, a chlorido ligand and the coordination to arsenic. In turn, arsenic is coordinated by two oxygen donor atoms, two hydroxyl ligands and by platinum(II), completing a trigonal–bipyramidal coordination sphere (Fig. 1 ▸). The first (ODOHAS) of the other two structure reports with a chlorido[dihydroxybis(1-iminoethoxy)]arsanido]platinum(II) molecule (Miodragović et al., 2013 ▸) is different from (1) because of an acetamide solvent molecule in the unit cell and a different space group (P21/n), and the second (ODOHEW) crystallizes in the same space group as (1) (P
) but with acetamide and hemihydrate solvent molecules in the unit cell. The bond lengths in the title compound compare very well with those in the two structures in literature. The Pt—As bond length of 2.2730 (12) Å and the Pt—Cl bond length of 2.3401 (15) Å are similar to 2.2732 (3) and 2.3272 (8) Å for ODOHEW, and 2.2729 (2) and 2.3328 (6) Å for ODOHAS. The Pt—N bond lengths vary between 1.999 (4) and 2.005 (4) Å, the As—O bond lengths between 1.898 (3) and 2.107 (3) Å, and the As—OH bond lengths between 1.722 (3) and 1.738 (3) Å. Overall, these molecular structures compare well. When comparing the Pt—As and Pt—Cl bond lengths to those of other platinum(II) complexes where As and Cl are in trans positions, it is clear that the Pt—As bond lengths do not vary significantly and range between 2.3333 (6) and 2.3599 (2) Å, while for the Pt—Cl bond lengths a greater variation is seen, in a range from 2.2917 (4) to 2.3927 (5) Å (Reinholdt & Bendix, 2017 ▸; Clegg, 2016 ▸; Dube et al., 2016 ▸; Imoto et al., 2017 ▸; Muessig et al., 2019 ▸). While the Pt—Cl length in (1) compares well with these trans complexes, the Pt—As bond length is somewhat smaller. The square-planar coordination around the central platinum(II) atom is distorted with N1—Pt1—N2 and N1—Pt1—As1 being 173.90 (13) and 85.18 (11)°, respectively, deviating from the expected 180 and 90°. The trigonal–bipyramidal coordination around the arsenic atom is significantly distorted with O4—As1—O6, O1—As1—O2 and O1—As1—Pt1 being 106.98 (14), 174.04 (11) and 95.35 (10)°, deviating from the ideal 120, 180 and 90°, respectively. Considering arsenic with a coordination number of 5, the index τ
5 parameter can be used to calculate any potential distortion (Addison et al., 1984 ▸). The τ
5 parameter is defined as (β – α)/60° with β the largest and α the second largest angle in the coordination sphere and was calculated as 0.794 for (1), suggesting a significantly distorted trigonal–bipyramidal shape around arsenic (τ
5 = 0 for an ideal square pyramid and 1 for an ideal trigonal bipyramid).
Figure 1.
Molecular structures of (1) and (2), indicating the numbering schemes. Displacement ellipsoids are drawn at a probability level of 50%.
The coordination environments of the platinum and arsenic atoms in (2) are the same as in (1), i.e. Pt1 is coordinated by a chlorido ligand, two nitrogen donor atoms and arsenic, that is additionally bonded to two hydroxyl ligands and two oxygen donor atoms (Fig. 1 ▸). The Pt—As and Pt—Cl bond lengths of 2.2672 (8) Å and 2.3387 (11) Å in (2) are virtually identical with the bond lengths of 2.2687 (4) Å and 2.3361 (9) Å, respectively, in the orthorhombic polymorph reported by Miodragović et al. (2013 ▸). Again, these Pt—As and Pt—Cl bond lengths fit well into the ranges reported for other structures where As and Cl are in trans positions. The square-planar coordination environment around the platinum(II) atom is similarly distorted in the structures of the two polymorphs, with the ideal 180° (N—Pt—N) and 90° (N—Pt—Cl) angles deviating at 173.59 (13) and 94.68 (9)° for the structure determined by Miodragović et al. (2013 ▸) and 173.20 (14) (N1—Pt1—N2) and 94.16 (11)° (N1—Pt1—Cl1) for (2), respectively. The largest deviation of the trigonal–bipyramidal coordination sphere of the arsenic atom in the polymorphic structures pertains to the Pt—As—OH angle, with reported values of 129.78 (10) and 124.67 (9)° for the orthorhombic structure (Miodragović et al., 2013 ▸) and of 130.05 (11) and 124.46 (9)° for (2). The τ5 parameter for (2) is calculated as 0.711.
When comparing the molecules of (1) and (2), it is clear that they do not differ much in terms of bond lengths and angles, with the only structural difference being the alkyl substituent on the ligand, viz. in (1) an ethyl and in (2) a propyl chain. The bond lengths around platinum are all similar (Pt—As, Pt—Cl, Pt—N) as well as the two pairs of As—OH distances. There is a slight variation in the As—O bond lengths, 1.898 (3) and 2.107 (3) Å for (1) and 1.946 (3) and 1.979 (3) Å for (2). The N1—Pt1—N2 bond angles are similar [173.90 (13)° for (1) and 173.20 (14)° for (2)] while there are slight differences for the N—Pt1—As1 and N—Pt—Cl1 bond angles: 85.18 (11) and 89.42 (11)° for (1), and 87.25 (10) and 86.05 (10)° for (2) (N1—Pt1—As1, N2—Pt1—As1), and 93.28 (11) and 92.34 (11)° for (1) and 94.16 (11) and 92.53 (10)° for (2) (N1—Pt1—Cl1, N2—Pt1—Cl1). The As1—Pt1—Cl1 bond angles also vary being 174.79 (3) and 178.51 (3)° for (1) and (2). The bond angles around arsenic are all in a similar range but have more variation in some of the angles, for instance 126.42 (10) and 130.05 (11)° (O6—As1—Pt1), 90.24 (9) and 94.20 (9)° (O2—As1—Pt1), and 95.35 (10) and 93.12 (8)° (O1—As1—Pt1) for (1) and (2 ), respectively. The trigonal– bipyramidal coordination environment around arsenic is distorted in both molecules with a τ5 parameter value of 0.794 and 0.711 for (1) and (2). Thus, the As atom in (2) shows a slightly higher distortion than in (1).
Supramolecular features
In the crystal structure of (1), six hydrogen-bonding interactions are observed (Table 1 ▸), five intermolecular (N1—H1⋯O4i, N2—H2⋯O6ii, O4—H4⋯O2iii, O6—H6⋯Cl1iv, C3—H3B⋯Clv) and one intramolecular (O6—H6⋯O2), as illustrated in Fig. 2 ▸. Bifurcation creates inter- and intramolecular interactions that can contribute to the stability of the structure. One of the donor hydrogen atoms (H6) takes part in hydrogen-bonding interactions to an oxygen atom (O2) and a chloride atom (Cl1) and forms an unsymmetrical bifurcated bond. Overall, the four stronger intermolecular hydrogen-bonding interactions sustain an infinite three-dimensional framework (Fig. 3 ▸). An intermolecular cluster is formed from the strongest hydrogen-bonding interaction [O4⋯O2iii = 2.750 (4) Å], which generates an infinite chain along the c-axis direction (as can be seen in Fig. 3 ▸). Various π-interactions are also observed in (1), defined by the platinum(II) atom of one molecule to the centroid of the (Pt1,As1,C2,N2,O2) ring with a Pt⋯centroid distance of 3.7225 (7) Å, by the centroid of the (Pt1,As1,C2,N2,O2) ring to the centroid of the (Pt1,As1,C2,N2,O2) (−x, −y, 1 − z) ring of an adjacent molecule with a distance of 3.7456 (4) Å, and by the centroid of the (Pt1,As1,C1,N1,O1) ring to the centroid of another (Pt1,As1,C1,N1,O2) (−x, −y, −z) ring with a distance of 3.7960 (6) Å (Fig. 4 ▸). When viewed along the c axis, individual molecules pack in ‘column-like’ structures in an alternating head-to-tail fashion, as illustrated in Fig. 3 ▸.
Table 1. Hydrogen-bond geometry (Å, °) for 1 .
| D—H⋯A | D—H | H⋯A | D⋯A | D—H⋯A |
|---|---|---|---|---|
| N1—H1⋯O4i | 0.901 (19) | 2.50 (5) | 3.077 (5) | 122 (4) |
| N2—H2⋯O6ii | 0.90 (2) | 2.51 (4) | 3.280 (5) | 143 (5) |
| O4—H4⋯O2iii | 0.821 (19) | 1.93 (2) | 2.750 (4) | 173 (6) |
| O6—H6⋯O2 | 0.827 (19) | 2.27 (5) | 2.643 (4) | 108 (4) |
| O6—H6⋯Cl1iv | 0.827 (19) | 2.45 (3) | 3.191 (3) | 149 (5) |
| C3—H3B⋯Cl1v | 0.96 | 2.72 | 3.613 (5) | 155 |
Symmetry codes: (i)
; (ii)
; (iii)
; (iv)
; (v)
.
Figure 2.
Hydrogen-bonding interactions (indicated by purple dashed lines) observed in the structures of (1) and (2). Hydrogen atoms not involved in hydrogen-bonding interactions were omitted for clarity.
Figure 3.
Illustration of the infinite three-dimensional frameworks formed by the hydrogen-bonding interactions in (1) and (2). Blue dashed lines indicate the infinite networks along the a axes, purple dashed lines along the b axes and gold dashed lines along the c axes. Hydrogen atoms not involved in the interactions were omitted for clarity.
Figure 4.
π-interactions observed in the crystal structures of (1) and (2). Hydrogen atoms were omitted for clarity.
The crystal structure of (2) is likewise stabilized by one intramolecular (O6—H6⋯O1) and five intermolecular (N1—H1⋯O6i, N2—H2⋯Cl1ii, O4—H4⋯Cl1iii, O6—H6⋯O4iv, C6—H6A⋯Cl1ii) hydrogen-bonding interactions (Table 2 ▸, Fig. 2 ▸), again with an unsymmetrical bifurcated hydrogen bond involving atom H6 (bonding to O1 and O4) and a resulting three-dimensional network structure, as illustrated in Fig. 3 ▸. In addition, Cl1 is the acceptor of two hydrogen-bonding interactions. Two weak π-interactions are also observed in (2), one from Pt1 to the centroid of Pt1,As1,O1,C1,N1 with a distance of 3.8213 (2) Å and the other from Cl1 to a symmetry-related centroid (Pt1,As1,O1,C1,N1; 1 − x, −y, −z) with a distance of 3.8252 (12) Å (Fig. 4 ▸).
Table 2. Hydrogen-bond geometry (Å, °) for 2 .
| D—H⋯A | D—H | H⋯A | D⋯A | D—H⋯A |
|---|---|---|---|---|
| N1—H1⋯O6i | 0.88 (5) | 2.19 (5) | 3.041 (4) | 163 (5) |
| N2—H2⋯Cl1ii | 0.854 (19) | 2.71 (4) | 3.408 (4) | 140 (4) |
| O4—H4⋯Cl1iii | 0.82 | 2.28 | 3.071 (3) | 161 |
| O6—H6⋯O1 | 0.82 | 2.34 | 2.608 (4) | 100 |
| O6—H6⋯O4iv | 0.82 | 1.92 | 2.712 (4) | 162 |
| C6—H6A⋯Cl1ii | 0.96 | 2.82 | 3.735 (5) | 159 |
Symmetry codes: (i)
; (ii)
; (iii)
; (iv)
.
In comparison, molecules in (1) and (2) pack differently due to the presence of different alkyl chains (Fig. 3 ▸).
Synthesis and crystallization
Synthesis of 1
K2PtCl4 (416 mg, 1 mmol) was added to a 125 ml solution of 9:1 (v:v) CH3CN/H2O. The mixture was stirred at 363 K. Once the K2PtCl4 had dissolved, As2O3 (405 mg, 2.05 mmol) was added to the solution and refluxed at 363 K for 48 h. The mixture was then filtered, and the filtrate was left to stand at room temperature. Crystals suitable for X-ray crystallography were obtained by slow evaporation. Yield: 301 mg (66%). 1H NMR (300.18 MHz, dimethyl sulfoxide-d 6): σ = 7.30 (OH, 2H,s), 6.69 (NH, 2H,s), 1.75 (CH3, 6H, s) ppm. 13C NMR (150.95 MHz, dimethyl sulfoxide-d 6): σ =172 (CN), 23 (CH3) ppm. 195Pt NMR (242.99 MHz, dimethyl sulfoxide-d 6): σ = −3590.62 ppm. UV/Vis = λ = 285 nm, ∊ = 4029 dm3 mol−1 cm−1. Analysis calculated: C, 10.55; H, 2.21; N, 6.15. Found: C, 10.64; H, 2.22; N, 6.09%.
Synthesis of 2
K2PtCl4 (422 mg, 1.02 mmol) was added to a 50 ml solution of 9:1 (v:v) H2O/CH3CH2CN. The mixture was stirred at room temperature. Once the K2PtCl4 had dissolved, As2O3 (400 mg, 2.02 mmol) was added to the solution and was stirred at room temperature for 96 h. The solution was cooled in an ice bath and then filtered. The filtrate was left to stand at room temperature. Crystals suitable for X-ray crystallography were obtained by slow evaporation. Yield: 278 mg (56%). 1H NMR (600.28 MHz, dimethyl sulfoxide-d 6): δ = 8.89 (OH, 2H, s), 7.99 (NH, 2H, s), 2.48 (CH2, 4H, q), 1.04 (CH3, 6H, t). 13C NMR (150.95 MHz, dimethyl sulfoxide-d 6): δ = 176.18 (CN), 24.53 (CH2), 11.70 (CH3). 195Pt NMR (242.99 MHz, dimethyl sulfoxide-d 6) = −3591.52. UV/Vis: λmax = 270 nm, ∊ = 4231 L mol−1 cm−1. Analysis calculated C, 14.90; H, 2.92; N, 5.79. Found: C, 14.82; H, 2.91; N, 5.76.
Refinement
Crystal data and details of data collections and structure refinements are summarized in Table 3 ▸. Methyl and methylene hydrogen atoms were placed in geometrically idealized positions (C—H = 0.95–0.97 Å) and constrained to ride on their parent atoms [U iso(H) = 1.5U eq(C) and 1.2U eq(C)]. The OH and NH hydrogen atoms were located in a difference-Fourier map and their positional parameters were constrained with O—H = 0.84 (2) Å and N—H = 0.89 (2) Å for (1), and N—H = 0.87 (2) Å for (2) with O—H distances fixed at 0.82 Å and with U iso(H) = 1.5U eq(O). For (2), the Fc versus Fo plot proved ten reflections to be outliers, and they were removed from the refinement as systematic errors.
Table 3. Experimental details.
| (1) | 2 | |
|---|---|---|
| Crystal data | ||
| Chemical formula | [PtCl(C4H10AsN2O4)] | [Pt(C6H14AsN2O4)Cl] |
| M r | 455.59 | 483.65 |
| Crystal system, space group | Triclinic, P
|
Monoclinic, P21/c |
| Temperature (K) | 100 | 100 |
| a, b, c (Å) | 7.272 (1), 8.099 (1), 9.350 (2) | 8.9009 (3), 14.1270 (5), 9.6438 (3) |
| α, β, γ (°) | 66.588 (5), 83.993 (5), 76.737 (5) | 90, 98.243 (2), 90 |
| V (Å3) | 491.81 (14) | 1200.11 (9) |
| Z | 2 | 4 |
| Radiation type | Mo Kα | Mo Kα |
| μ (mm−1) | 17.86 | 14.65 |
| Crystal size (mm) | 0.39 × 0.29 × 0.14 | 0.55 × 0.42 × 0.08 |
| Data collection | ||
| Diffractometer | Bruker APEXII CCD | Bruker APEXII CCD |
| Absorption correction | Multi-scan (SADABS; Bruker, 2012 ▸) | Multi-scan (SADABS; Bruker, 2012 ▸) |
| T min, T max | 0.003, 0.090 | 0.001, 0.301 |
| No. of measured, independent and observed [I > 2σ(I)] reflections | 8305, 2435, 2345 | 41298, 2891, 2700 |
| R int | 0.039 | 0.047 |
| (sin θ/λ)max (Å−1) | 0.667 | 0.661 |
| Refinement | ||
| R[F 2 > 2σ(F 2)], wR(F 2), S | 0.020, 0.052, 1.18 | 0.022, 0.081, 1.05 |
| No. of reflections | 2411 | 2891 |
| No. of parameters | 136 | 148 |
| No. of restraints | 4 | 1 |
| H-atom treatment | H atoms treated by a mixture of independent and constrained refinement | H atoms treated by a mixture of independent and constrained refinement |
| Δρmax, Δρmin (e Å−3) | 0.79, −2.05 | 1.53, −1.98 |
Supplementary Material
Crystal structure: contains datablock(s) global, 1, 2. DOI: 10.1107/S2056989019016463/wm5532sup1.cif
Additional supporting information: crystallographic information; 3D view; checkCIF report
supplementary crystallographic information
Chlorido[dihydroxybis(1-iminoethoxy)arsanido-κN,As,N']platinum(II) (1) . Crystal data
| [Pt(C4H10AsN2O4)Cl] | Z = 2 |
| Mr = 455.59 | F(000) = 416 |
| Triclinic, P1 | Dx = 3.076 Mg m−3 |
| Hall symbol: -P 1 | Mo Kα radiation, λ = 0.71069 Å |
| a = 7.272 (1) Å | Cell parameters from 6890 reflections |
| b = 8.099 (1) Å | θ = 3.6–28.3° |
| c = 9.350 (2) Å | µ = 17.86 mm−1 |
| α = 66.588 (5)° | T = 100 K |
| β = 83.993 (5)° | Cuboid, colourless |
| γ = 76.737 (5)° | 0.39 × 0.29 × 0.14 mm |
| V = 491.81 (14) Å3 |
Chlorido[dihydroxybis(1-iminoethoxy)arsanido-κN,As,N']platinum(II) (1) . Data collection
| Bruker APEXII CCD diffractometer | 2345 reflections with I > 2σ(I) |
| φ and ω scans | Rint = 0.039 |
| Absorption correction: multi-scan (SADABS; Bruker, 2012) | θmax = 28.3°, θmin = 3.8° |
| Tmin = 0.003, Tmax = 0.090 | h = −9→9 |
| 8305 measured reflections | k = −8→10 |
| 2435 independent reflections | l = −12→12 |
Chlorido[dihydroxybis(1-iminoethoxy)arsanido-κN,As,N']platinum(II) (1) . Refinement
| Refinement on F2 | 4 restraints |
| Least-squares matrix: full | Hydrogen site location: mixed |
| R[F2 > 2σ(F2)] = 0.020 | H atoms treated by a mixture of independent and constrained refinement |
| wR(F2) = 0.052 | w = 1/[σ2(Fo2) + (0.017P)2 + 1.0064P] where P = (Fo2 + 2Fc2)/3 |
| S = 1.18 | (Δ/σ)max = 0.001 |
| 2411 reflections | Δρmax = 0.79 e Å−3 |
| 136 parameters | Δρmin = −2.04 e Å−3 |
Chlorido[dihydroxybis(1-iminoethoxy)arsanido-κN,As,N']platinum(II) (1) . Special details
| Geometry. All esds (except the esd in the dihedral angle between two l.s. planes) are estimated using the full covariance matrix. The cell esds are taken into account individually in the estimation of esds in distances, angles and torsion angles; correlations between esds in cell parameters are only used when they are defined by crystal symmetry. An approximate (isotropic) treatment of cell esds is used for estimating esds involving l.s. planes. |
Chlorido[dihydroxybis(1-iminoethoxy)arsanido-κN,As,N']platinum(II) (1) . Fractional atomic coordinates and isotropic or equivalent isotropic displacement parameters (Å2)
| x | y | z | Uiso*/Ueq | ||
| Pt1 | 0.07024 (2) | 0.05975 (2) | 0.24814 (2) | 0.00525 (6) | |
| As1 | −0.10555 (5) | −0.15921 (5) | 0.31382 (4) | 0.00631 (9) | |
| Cl1 | 0.22859 (14) | 0.30050 (13) | 0.18937 (12) | 0.01233 (19) | |
| O4 | −0.0662 (4) | −0.3392 (4) | 0.2529 (3) | 0.0115 (6) | |
| O1 | −0.2849 (4) | −0.0205 (4) | 0.1539 (3) | 0.0113 (6) | |
| C3 | −0.3872 (6) | 0.2425 (6) | −0.0760 (5) | 0.0130 (8) | |
| H3B | −0.508229 | 0.285642 | −0.037137 | 0.019* | |
| H3A | −0.400172 | 0.162257 | −0.125455 | 0.019* | |
| H3C | −0.339248 | 0.345439 | −0.150284 | 0.019* | |
| C5 | 0.3527 (6) | −0.3940 (6) | 0.6461 (5) | 0.0136 (8) | |
| H5A | 0.451272 | −0.333216 | 0.646809 | 0.02* | |
| H5C | 0.407126 | −0.505519 | 0.630569 | 0.02* | |
| H5B | 0.285185 | −0.422631 | 0.743999 | 0.02* | |
| O2 | 0.0724 (4) | −0.3296 (4) | 0.5035 (3) | 0.0098 (6) | |
| N2 | 0.2483 (5) | −0.1101 (5) | 0.4204 (4) | 0.0098 (7) | |
| O6 | −0.2912 (4) | −0.1890 (4) | 0.4486 (3) | 0.0109 (6) | |
| N1 | −0.1134 (5) | 0.2051 (5) | 0.0754 (4) | 0.0099 (7) | |
| C1 | −0.2535 (6) | 0.1403 (5) | 0.0559 (4) | 0.0083 (7) | |
| C2 | 0.2192 (6) | −0.2701 (5) | 0.5165 (5) | 0.0090 (7) | |
| H2 | 0.355 (5) | −0.091 (8) | 0.448 (6) | 0.025 (15)* | |
| H1 | −0.113 (8) | 0.314 (4) | −0.004 (5) | 0.025 (15)* | |
| H6 | −0.236 (7) | −0.202 (7) | 0.527 (4) | 0.017 (13)* | |
| H4 | −0.059 (8) | −0.438 (4) | 0.328 (5) | 0.026 (15)* |
Chlorido[dihydroxybis(1-iminoethoxy)arsanido-κN,As,N']platinum(II) (1) . Atomic displacement parameters (Å2)
| U11 | U22 | U33 | U12 | U13 | U23 | |
| Pt1 | 0.00569 (9) | 0.00337 (9) | 0.00559 (9) | −0.00199 (6) | −0.00017 (6) | −0.00001 (6) |
| As1 | 0.00695 (19) | 0.00417 (19) | 0.00666 (18) | −0.00267 (14) | −0.00050 (14) | 0.00001 (14) |
| Cl1 | 0.0149 (5) | 0.0096 (4) | 0.0132 (4) | −0.0071 (4) | 0.0013 (4) | −0.0029 (4) |
| O4 | 0.0210 (15) | 0.0055 (13) | 0.0089 (13) | −0.0049 (11) | −0.0006 (11) | −0.0024 (11) |
| O1 | 0.0107 (14) | 0.0101 (14) | 0.0100 (13) | −0.0045 (11) | −0.0032 (11) | 0.0013 (11) |
| C3 | 0.0101 (19) | 0.014 (2) | 0.0105 (18) | 0.0002 (15) | −0.0032 (15) | −0.0015 (15) |
| C5 | 0.0084 (18) | 0.0122 (19) | 0.0143 (19) | −0.0030 (15) | −0.0055 (15) | 0.0029 (15) |
| O2 | 0.0107 (14) | 0.0059 (13) | 0.0098 (13) | −0.0049 (10) | −0.0003 (11) | 0.0016 (11) |
| N2 | 0.0068 (16) | 0.0103 (17) | 0.0109 (16) | −0.0039 (13) | −0.0017 (13) | −0.0010 (13) |
| O6 | 0.0062 (13) | 0.0161 (14) | 0.0095 (13) | −0.0038 (11) | 0.0006 (11) | −0.0034 (11) |
| N1 | 0.0128 (17) | 0.0059 (16) | 0.0091 (16) | −0.0024 (13) | −0.0009 (13) | −0.0005 (13) |
| C1 | 0.0108 (18) | 0.0048 (17) | 0.0065 (17) | 0.0022 (14) | −0.0007 (14) | −0.0013 (14) |
| C2 | 0.0082 (18) | 0.0074 (18) | 0.0092 (17) | 0.0002 (14) | 0.0004 (14) | −0.0021 (14) |
Chlorido[dihydroxybis(1-iminoethoxy)arsanido-κN,As,N']platinum(II) (1) . Geometric parameters (Å, º)
| Pt1—N1 | 1.999 (4) | C3—H3A | 0.96 |
| Pt1—N2 | 2.005 (4) | C3—H3C | 0.96 |
| Pt1—As1 | 2.2730 (12) | C5—C2 | 1.501 (5) |
| Pt1—Cl1 | 2.3401 (15) | C5—H5A | 0.96 |
| As1—O4 | 1.722 (3) | C5—H5C | 0.96 |
| As1—O6 | 1.738 (3) | C5—H5B | 0.96 |
| As1—O1 | 1.898 (3) | O2—C2 | 1.302 (5) |
| As1—O2 | 2.107 (3) | N2—C2 | 1.301 (5) |
| O4—H4 | 0.821 (19) | N2—H2 | 0.90 (2) |
| O1—C1 | 1.316 (5) | O6—H6 | 0.827 (19) |
| C3—C1 | 1.491 (5) | N1—C1 | 1.306 (5) |
| C3—H3B | 0.96 | N1—H1 | 0.901 (19) |
| N1—Pt1—N2 | 173.90 (13) | H3B—C3—H3C | 109.5 |
| N1—Pt1—As1 | 85.18 (11) | H3A—C3—H3C | 109.5 |
| N2—Pt1—As1 | 89.42 (11) | C2—C5—H5A | 109.5 |
| N1—Pt1—Cl1 | 93.28 (11) | C2—C5—H5C | 109.5 |
| N2—Pt1—Cl1 | 92.34 (11) | H5A—C5—H5C | 109.5 |
| As1—Pt1—Cl1 | 174.79 (3) | C2—C5—H5B | 109.5 |
| O4—As1—O6 | 106.98 (14) | H5A—C5—H5B | 109.5 |
| O4—As1—O1 | 90.06 (14) | H5C—C5—H5B | 109.5 |
| O6—As1—O1 | 88.71 (14) | C2—O2—As1 | 116.5 (2) |
| O4—As1—O2 | 88.29 (13) | C2—N2—Pt1 | 122.5 (3) |
| O6—As1—O2 | 86.29 (13) | C2—N2—H2 | 109 (4) |
| O1—As1—O2 | 174.04 (11) | Pt1—N2—H2 | 129 (4) |
| O4—As1—Pt1 | 126.37 (10) | As1—O6—H6 | 100 (4) |
| O6—As1—Pt1 | 126.42 (10) | C1—N1—Pt1 | 121.7 (3) |
| O1—As1—Pt1 | 95.35 (10) | C1—N1—H1 | 109 (4) |
| O2—As1—Pt1 | 90.24 (9) | Pt1—N1—H1 | 130 (4) |
| As1—O4—H4 | 111 (4) | N1—C1—O1 | 121.2 (4) |
| C1—O1—As1 | 116.4 (3) | N1—C1—C3 | 122.7 (4) |
| C1—C3—H3B | 109.5 | O1—C1—C3 | 116.1 (4) |
| C1—C3—H3A | 109.5 | N2—C2—O2 | 121.1 (4) |
| H3B—C3—H3A | 109.5 | N2—C2—C5 | 121.7 (4) |
| C1—C3—H3C | 109.5 | O2—C2—C5 | 117.2 (3) |
| O4—As1—O1—C1 | −123.0 (3) | As1—O1—C1—C3 | 175.8 (3) |
| O6—As1—O1—C1 | 130.0 (3) | Pt1—N2—C2—O2 | 1.2 (6) |
| Pt1—As1—O1—C1 | 3.5 (3) | Pt1—N2—C2—C5 | −179.1 (3) |
| Pt1—N1—C1—O1 | 3.2 (6) | As1—O2—C2—N2 | 2.8 (5) |
| Pt1—N1—C1—C3 | −177.2 (3) | As1—O2—C2—C5 | −177.0 (3) |
| As1—O1—C1—N1 | −4.6 (5) |
Chlorido[dihydroxybis(1-iminoethoxy)arsanido-κN,As,N']platinum(II) (1) . Hydrogen-bond geometry (Å, º)
| D—H···A | D—H | H···A | D···A | D—H···A |
| N1—H1···O4i | 0.901 (19) | 2.50 (5) | 3.077 (5) | 122 (4) |
| N2—H2···O6ii | 0.90 (2) | 2.51 (4) | 3.280 (5) | 143 (5) |
| O4—H4···O2iii | 0.821 (19) | 1.93 (2) | 2.750 (4) | 173 (6) |
| O6—H6···O2 | 0.827 (19) | 2.27 (5) | 2.643 (4) | 108 (4) |
| O6—H6···Cl1iv | 0.827 (19) | 2.45 (3) | 3.191 (3) | 149 (5) |
| C3—H3B···Cl1v | 0.96 | 2.72 | 3.613 (5) | 155 |
Symmetry codes: (i) −x, −y, −z; (ii) x+1, y, z; (iii) −x, −y−1, −z+1; (iv) −x, −y, −z+1; (v) x−1, y, z.
Chlorido[dihydroxybis(1-iminopropoxy)arsanido-κN,As,N']platinum(II) (2) . Crystal data
| [Pt(C6H14AsN2O4)Cl] | F(000) = 896 |
| Mr = 483.65 | Dx = 2.677 Mg m−3 |
| Monoclinic, P21/c | Mo Kα radiation, λ = 0.71069 Å |
| Hall symbol: -P 2ybc | Cell parameters from 9966 reflections |
| a = 8.9009 (3) Å | θ = 3.6–28.4° |
| b = 14.1270 (5) Å | µ = 14.65 mm−1 |
| c = 9.6438 (3) Å | T = 100 K |
| β = 98.243 (2)° | Plate, colourless |
| V = 1200.11 (9) Å3 | 0.55 × 0.42 × 0.08 mm |
| Z = 4 |
Chlorido[dihydroxybis(1-iminopropoxy)arsanido-κN,As,N']platinum(II) (2) . Data collection
| Bruker APEXII CCD diffractometer | 2700 reflections with I > 2σ(I) |
| φ and ω scans | Rint = 0.047 |
| Absorption correction: multi-scan (SADABS; Bruker, 2012) | θmax = 28.0°, θmin = 4.4° |
| Tmin = 0.001, Tmax = 0.301 | h = −11→11 |
| 41298 measured reflections | k = −18→18 |
| 2891 independent reflections | l = −12→12 |
Chlorido[dihydroxybis(1-iminopropoxy)arsanido-κN,As,N']platinum(II) (2) . Refinement
| Refinement on F2 | Primary atom site location: heavy-atom method |
| Least-squares matrix: full | Hydrogen site location: mixed |
| R[F2 > 2σ(F2)] = 0.022 | H atoms treated by a mixture of independent and constrained refinement |
| wR(F2) = 0.081 | w = 1/[σ2(Fo2) + (0.0629P)2 + 1.201P] where P = (Fo2 + 2Fc2)/3 |
| S = 1.05 | (Δ/σ)max < 0.001 |
| 2891 reflections | Δρmax = 1.53 e Å−3 |
| 148 parameters | Δρmin = −1.97 e Å−3 |
| 1 restraint |
Chlorido[dihydroxybis(1-iminopropoxy)arsanido-κN,As,N']platinum(II) (2) . Special details
| Geometry. All esds (except the esd in the dihedral angle between two l.s. planes) are estimated using the full covariance matrix. The cell esds are taken into account individually in the estimation of esds in distances, angles and torsion angles; correlations between esds in cell parameters are only used when they are defined by crystal symmetry. An approximate (isotropic) treatment of cell esds is used for estimating esds involving l.s. planes. |
Chlorido[dihydroxybis(1-iminopropoxy)arsanido-κN,As,N']platinum(II) (2) . Fractional atomic coordinates and isotropic or equivalent isotropic displacement parameters (Å2)
| x | y | z | Uiso*/Ueq | ||
| Pt1 | 0.33235 (2) | 0.06675 (2) | 0.08616 (2) | 0.00918 (9) | |
| As1 | 0.47791 (4) | 0.19900 (3) | 0.11318 (4) | 0.00918 (11) | |
| Cl1 | 0.17867 (12) | −0.06796 (6) | 0.05304 (12) | 0.0183 (2) | |
| O4 | 0.6100 (3) | 0.2309 (2) | 0.0038 (3) | 0.0127 (5) | |
| H4 | 0.676165 | 0.190233 | 0.007601 | 0.019* | |
| O1 | 0.6421 (3) | 0.13513 (19) | 0.2392 (3) | 0.0127 (5) | |
| O6 | 0.4810 (3) | 0.2897 (2) | 0.2331 (3) | 0.0150 (6) | |
| H6 | 0.524135 | 0.27179 | 0.309457 | 0.022* | |
| C5 | 0.1062 (5) | 0.2938 (3) | −0.1667 (4) | 0.0168 (8) | |
| H5B | 0.167052 | 0.336047 | −0.21515 | 0.02* | |
| H5A | 0.047602 | 0.332619 | −0.110998 | 0.02* | |
| C2 | 0.2107 (5) | 0.2323 (3) | −0.0697 (4) | 0.0127 (7) | |
| N2 | 0.1856 (4) | 0.1445 (2) | −0.0450 (3) | 0.0134 (6) | |
| C4 | 0.7743 (6) | 0.0425 (4) | 0.5043 (5) | 0.0297 (10) | |
| H4B | 0.79075 | 0.109321 | 0.495994 | 0.045* | |
| H4A | 0.861994 | 0.014145 | 0.557876 | 0.045* | |
| H4C | 0.68723 | 0.032054 | 0.550648 | 0.045* | |
| O2 | 0.3329 (3) | 0.27611 (19) | −0.0081 (3) | 0.0130 (5) | |
| C1 | 0.6203 (5) | 0.0463 (3) | 0.2667 (4) | 0.0119 (7) | |
| C3 | 0.7473 (5) | −0.0015 (3) | 0.3597 (4) | 0.0180 (8) | |
| H3B | 0.8395 | 0.002883 | 0.317329 | 0.022* | |
| H3A | 0.723211 | −0.068067 | 0.368096 | 0.022* | |
| N1 | 0.4959 (4) | 0.0020 (2) | 0.2166 (3) | 0.0129 (6) | |
| C6 | −0.0037 (5) | 0.2407 (3) | −0.2757 (5) | 0.0260 (10) | |
| H6B | 0.052289 | 0.198648 | −0.327478 | 0.039* | |
| H6C | −0.058897 | 0.285263 | −0.338787 | 0.039* | |
| H6A | −0.073555 | 0.204823 | −0.229549 | 0.039* | |
| H1 | 0.489 (6) | −0.057 (4) | 0.244 (6) | 0.026 (17)* | |
| H2 | 0.106 (4) | 0.120 (4) | −0.090 (5) | 0.023 (14)* |
Chlorido[dihydroxybis(1-iminopropoxy)arsanido-κN,As,N']platinum(II) (2) . Atomic displacement parameters (Å2)
| U11 | U22 | U33 | U12 | U13 | U23 | |
| Pt1 | 0.01054 (13) | 0.00700 (12) | 0.00989 (12) | −0.00034 (4) | 0.00112 (8) | −0.00025 (4) |
| As1 | 0.0127 (2) | 0.00657 (19) | 0.00790 (18) | −0.00061 (13) | 0.00022 (15) | −0.00002 (12) |
| Cl1 | 0.0126 (5) | 0.0103 (5) | 0.0318 (6) | −0.0023 (3) | 0.0029 (4) | −0.0018 (3) |
| O4 | 0.0132 (14) | 0.0138 (12) | 0.0109 (11) | −0.0004 (10) | 0.0009 (10) | 0.0029 (10) |
| O1 | 0.0149 (14) | 0.0097 (12) | 0.0127 (12) | −0.0006 (10) | −0.0008 (10) | 0.0028 (10) |
| O6 | 0.0258 (16) | 0.0084 (13) | 0.0092 (12) | 0.0020 (11) | −0.0026 (11) | −0.0014 (9) |
| C5 | 0.014 (2) | 0.0172 (19) | 0.0180 (18) | 0.0012 (15) | −0.0003 (15) | 0.0040 (15) |
| C2 | 0.0152 (19) | 0.0142 (18) | 0.0086 (15) | 0.0040 (15) | 0.0014 (13) | −0.0010 (13) |
| N2 | 0.0125 (16) | 0.0132 (16) | 0.0143 (15) | −0.0009 (13) | 0.0008 (13) | 0.0009 (12) |
| C4 | 0.032 (3) | 0.035 (3) | 0.019 (2) | 0.010 (2) | −0.0082 (19) | −0.001 (2) |
| O2 | 0.0139 (14) | 0.0104 (12) | 0.0139 (12) | −0.0002 (10) | −0.0010 (10) | 0.0018 (10) |
| C1 | 0.016 (2) | 0.0103 (16) | 0.0107 (16) | 0.0016 (15) | 0.0053 (14) | −0.0001 (13) |
| C3 | 0.020 (2) | 0.0132 (18) | 0.0191 (18) | 0.0038 (15) | −0.0020 (16) | 0.0029 (14) |
| N1 | 0.0178 (17) | 0.0085 (15) | 0.0122 (14) | 0.0028 (12) | 0.0013 (12) | 0.0019 (12) |
| C6 | 0.023 (2) | 0.029 (2) | 0.022 (2) | 0.0019 (18) | −0.0081 (18) | 0.0108 (18) |
Chlorido[dihydroxybis(1-iminopropoxy)arsanido-κN,As,N']platinum(II) (2) . Geometric parameters (Å, º)
| Pt1—N1 | 2.003 (3) | C2—N2 | 1.289 (5) |
| Pt1—N2 | 2.010 (3) | C2—O2 | 1.316 (5) |
| Pt1—As1 | 2.2672 (8) | N2—H2 | 0.854 (19) |
| Pt1—Cl1 | 2.3387 (11) | C4—C3 | 1.514 (6) |
| As1—O6 | 1.724 (3) | C4—H4B | 0.96 |
| As1—O4 | 1.747 (3) | C4—H4A | 0.96 |
| As1—O2 | 1.946 (3) | C4—H4C | 0.96 |
| As1—O1 | 1.979 (3) | C1—N1 | 1.303 (5) |
| O4—H4 | 0.82 | C1—C3 | 1.500 (5) |
| O1—C1 | 1.303 (4) | C3—H3B | 0.97 |
| O6—H6 | 0.82 | C3—H3A | 0.97 |
| C5—C2 | 1.498 (5) | N1—H1 | 0.88 (5) |
| C5—C6 | 1.527 (6) | C6—H6B | 0.96 |
| C5—H5B | 0.97 | C6—H6C | 0.96 |
| C5—H5A | 0.97 | C6—H6A | 0.96 |
| N1—Pt1—N2 | 173.20 (14) | C2—N2—Pt1 | 121.9 (3) |
| N1—Pt1—As1 | 87.25 (10) | C2—N2—H2 | 117 (4) |
| N2—Pt1—As1 | 86.05 (10) | Pt1—N2—H2 | 121 (4) |
| N1—Pt1—Cl1 | 94.16 (11) | C3—C4—H4B | 109.5 |
| N2—Pt1—Cl1 | 92.53 (10) | C3—C4—H4A | 109.5 |
| As1—Pt1—Cl1 | 178.51 (3) | H4B—C4—H4A | 109.5 |
| O6—As1—O4 | 105.44 (14) | C3—C4—H4C | 109.5 |
| O6—As1—O2 | 86.12 (13) | H4B—C4—H4C | 109.5 |
| O4—As1—O2 | 86.48 (13) | H4A—C4—H4C | 109.5 |
| O6—As1—O1 | 89.28 (12) | C2—O2—As1 | 116.2 (2) |
| O4—As1—O1 | 89.27 (13) | O1—C1—N1 | 122.0 (4) |
| O2—As1—O1 | 172.68 (11) | O1—C1—C3 | 115.7 (4) |
| O6—As1—Pt1 | 130.05 (11) | N1—C1—C3 | 122.2 (4) |
| O4—As1—Pt1 | 124.46 (9) | C1—C3—C4 | 111.8 (4) |
| O2—As1—Pt1 | 94.20 (9) | C1—C3—H3B | 109.3 |
| O1—As1—Pt1 | 93.12 (8) | C4—C3—H3B | 109.3 |
| As1—O4—H4 | 109.5 | C1—C3—H3A | 109.3 |
| C1—O1—As1 | 116.5 (2) | C4—C3—H3A | 109.3 |
| As1—O6—H6 | 109.5 | H3B—C3—H3A | 107.9 |
| C2—C5—C6 | 115.1 (3) | C1—N1—Pt1 | 121.1 (3) |
| C2—C5—H5B | 108.5 | C1—N1—H1 | 116 (4) |
| C6—C5—H5B | 108.5 | Pt1—N1—H1 | 123 (4) |
| C2—C5—H5A | 108.5 | C5—C6—H6B | 109.5 |
| C6—C5—H5A | 108.5 | C5—C6—H6C | 109.5 |
| H5B—C5—H5A | 107.5 | H6B—C6—H6C | 109.5 |
| N2—C2—O2 | 121.5 (3) | C5—C6—H6A | 109.5 |
| N2—C2—C5 | 124.4 (4) | H6B—C6—H6A | 109.5 |
| O2—C2—C5 | 114.1 (3) | H6C—C6—H6A | 109.5 |
| C6—C5—C2—N2 | −21.3 (6) | As1—O1—C1—N1 | −1.4 (5) |
| C6—C5—C2—O2 | 159.6 (3) | As1—O1—C1—C3 | 178.6 (3) |
| O2—C2—N2—Pt1 | −1.3 (5) | O1—C1—C3—C4 | 63.1 (5) |
| C5—C2—N2—Pt1 | 179.8 (3) | N1—C1—C3—C4 | −116.9 (4) |
| N2—C2—O2—As1 | 3.5 (5) | O1—C1—N1—Pt1 | 2.7 (5) |
| C5—C2—O2—As1 | −177.5 (2) | C3—C1—N1—Pt1 | −177.4 (3) |
Chlorido[dihydroxybis(1-iminopropoxy)arsanido-κN,As,N']platinum(II) (2) . Hydrogen-bond geometry (Å, º)
| D—H···A | D—H | H···A | D···A | D—H···A |
| N1—H1···O6i | 0.88 (5) | 2.19 (5) | 3.041 (4) | 163 (5) |
| N2—H2···Cl1ii | 0.854 (19) | 2.71 (4) | 3.408 (4) | 140 (4) |
| O4—H4···Cl1iii | 0.82 | 2.28 | 3.071 (3) | 161 |
| O6—H6···O1 | 0.82 | 2.34 | 2.608 (4) | 100 |
| O6—H6···O4iv | 0.82 | 1.92 | 2.712 (4) | 162 |
| C6—H6A···Cl1ii | 0.96 | 2.82 | 3.735 (5) | 159 |
Symmetry codes: (i) −x+1, y−1/2, −z+1/2; (ii) −x, −y, −z; (iii) −x+1, −y, −z; (iv) x, −y+1/2, z+1/2.
Funding Statement
This work was funded by Universiteit van die Vrystaat grant . South African National Research Foundation grant .
References
- Aabo, K., Adams, M., Adnitt, P., Alberts, D. S., Athanazziou, A., Barley, V., Bell, D. R., Bianchi, U., Bolis, G., Brady, M. F., Brodovsky, H. S., Bruckner, H., Buyse, M., Canetta, R., Chylak, V., Cohen, C. J., Colombo, N., Conte, P. F., Crowther, D., Edmonson, J. H., Gennatas, C., Gilbey, E., Gore, M., Guthrie, D., Kaye, S., Laing, A., Landoni, F., Leonard, R., Lewis, C., Liu, P., Mangioni, C., Marsoni, S., Meerpohl, H., Omura, G., Parmar, M., Pater, J., Pecorelli, S., Presti, M., Sauerbrei, W., Skarlos, D., Smalley, R., Solomon, H., Stewart, L., Sturgeon, J., Tattersall, M., Wharton, J., ten Bokkel Huinink, W., Tomirotti, M., Torri, W., Trope, C., Turbow, M., Vermorken, J., Webb, M., Wilbur, D., Williams, C., Wiltshaw, E. & Yeap, B. (1998). Br. J. Cancer, 78, 1479–1487. [DOI] [PMC free article] [PubMed]
- Addison, A. W., Rao, T. N., Reedijk, J., van Rijn, J. & Verschoor, G. C. (1984). J. Chem. Soc. Dalton Trans. pp. 1349–1356.
- Basu, A. & Krishnamurthy, S. (2010). J. Nucleic Acids, 2010, 1–16. [DOI] [PMC free article] [PubMed]
- Brandenburg, K. & Putz, H. (2005). DIAMOND. Crystal Impact GbR, Bonn, Germany.
- Bruker (2012). APEX2, SAINT and SADABS. Bruker AXS Inc, Madison, Wisconsin, USA.
- Burchenal, J. H. (1978). Biochimie, 60, 915–923.
- Clegg, W. (2016). Private communication (refcode: CCDC 1470767). CCDC, Cambridge, England. https:/doi.org/10.5517/ccdc.csd.cc1lcg3j
- Dube, J. W., Zheng, Y., Thiel, W. & Alcarazo, M. (2016). J. Am. Chem. Soc. 138, 6869–6877. [DOI] [PubMed]
- Emadi, A. & Gore, S. D. (2010). Blood Rev. 24, 191–199. [DOI] [PMC free article] [PubMed]
- Farrugia, L. J. (2012). J. Appl. Cryst. 45, 849–854.
- Groom, C. R., Bruno, I. J., Lightfoot, M. P. & Ward, S. C. (2016). Acta Cryst. B72, 171–179. [DOI] [PMC free article] [PubMed]
- Imoto, H., Sasaki, H., Tanaka, S., Yumura, T. & Naka, K. (2017). Organometallics, 36, 2605–2611.
- Jakupec, M. A., Galanski, M. & Keppler, B. K. (2003). Rev. Physiol. Biochem. Pharmacol. 146, 1–54. [DOI] [PubMed]
- Kauffman, G. B., Pentimalli, R., Doldi, S. & Hall, M. D. (2010). Plat. Met. Rev. 54, 250–256.
- Kelland, L. (2007). Nat. Rev. Cancer, 7, 573–584. [DOI] [PubMed]
- Marino, T., Parise, A. & Russo, N. (2017). Phys. Chem. Chem. Phys. 19, 1328–1334. [DOI] [PubMed]
- Miller, W. H., Schipper, H. M., Lee, J. S., Singer, J. & Waxman, S. (2002). Cancer Res. 62, 3893–3903. [PubMed]
- Miodragović, D., Swindell, E. P., Waxali, Z. S., Bogachkov, A. & O’Halloran, T. V. (2019). Inorg. Chim. Acta, 496, 119030. [DOI] [PMC free article] [PubMed]
- Miodragović, D. U., Quentzel, J. A., Kurutz, J. W., Stern, C. L., Ahn, R. W., Kandela, I., Mazar, A. & O’Halloran, T. V. (2013). Angew. Chem. Int. Ed. 52, 10749–10752. [DOI] [PMC free article] [PubMed]
- Muessig, J. H., Stennett, T. E., Schmidt, U., Dewhurst, R. D., Mailänder, L. & Braunschweig, H. (2019). Dalton Trans. 48, 3547–3550. [DOI] [PubMed]
- Ott, I. (2009). Coord. Chem. Rev. 253, 1670–1681.
- Reedijk, J. (2009). Eur. J. Inorg. Chem. 2009, pp. 1303–1312.
- Reinholdt, A. & Bendix, J. (2017). Inorg. Chem. 56, 12492–12497. [DOI] [PubMed]
- Rosenberg, B., Van Camp, I. & Krigas, T. (1965). Nature, 205, 698–699. [DOI] [PubMed]
- Sheldrick, G. M. (2008). Acta Cryst. A64, 112–122. [DOI] [PubMed]
- Sheldrick, G. M. (2015). Acta Cryst. C71, 3–8.
- Shen, Z.-X., Shi, Z.-Z., Fang, J., Gu, B.-W., Li, J.-M., Zhu, Y.-M., Shi, J.-Y., Zheng, P.-Z., Yan, H., Liu, Y.-F., Chen, Y., Shen, Y., Wu, W., Tang, W., Waxman, S., De Thé, H., Wang, Z.-Y., Chen, S.-J. & Chen, Z. (2004). Proc. Natl Acad. Sci. USA, 101, 5328–5335.
- Shi, H., Clarkson, G. J. & Sadler, P. J. (2019). Inorg. Chim. Acta, 489, 230–235.
- Swindell, E. P., Hankins, P. L., Chen, H., Miodragović, D. U. & O’Halloran, T. V. (2013). Inorg. Chem. 52, 12292–12304. [DOI] [PMC free article] [PubMed]
- Wang, G., Li, W., Cui, J., Gao, S., Yao, C., Jiang, Z., Song, Y., Yuan, C. J., Yang, Y., Liu, Z. & Cai, L. (2004). Hematol. Oncol. 22, 63–71. [DOI] [PubMed]
- Wheate, N. J., Walker, S., Craig, G. E. & Oun, R. (2010). Dalton Trans. 39, 8113–8127. [DOI] [PubMed]
- Zhang, N., Wu, Z.-M., McGowan, E., Shi, J., Hong, Z.-B., Ding, C.-W., Xia, P. & Di, W. (2009). Cancer Sci. 100, 2459–2464. [DOI] [PMC free article] [PubMed]
- Zhang, X.-W., Yan, X.-J., Zhou, Z.-R., Yang, F.-F., Wu, Z.-Y., Sun, H.-B., Liang, W.-X., Song, A.-X., Lallemand-Breitenbach, V., Jeanne, M., Zhang, Q.-Y., Yang, H.-Y., Huang, Q.-H., Zhou, G.-B., Tong, J.-H., Zhang, Y., Wu, J.-H., Hu, H. Y., de Thé, H., Chen, S.-J. & Chen, Z. (2010). Science, 328, 240–243. [DOI] [PubMed]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Crystal structure: contains datablock(s) global, 1, 2. DOI: 10.1107/S2056989019016463/wm5532sup1.cif
Additional supporting information: crystallographic information; 3D view; checkCIF report




